Announcement PDF Company Announcement IMAGION BIOSYSTEMS LIMITED ASX: IBX 13 November 2023 Results of Extraordinary General Meeting MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detec on of cancer, having successfully completed the MagSense® HER2 Imaging Agent Phase 1 study (IBI10103), provides results of its Extraordinary General Mee ng held in Melbourne (and virtually) today. All resolu ons were carried on a poll. Details of the resolu ons, proxies received, and the votes cast on the poll in respect of each resolu on are set out in the a ached summary.  ENDS  About Imagion Biosystems Established in 2017 and headquartered in San Diego, California, US, Imagion Biosystems is an ASXlisted company dedicated to developing innova ve medical imaging technologies for various cancer types. Imagion Biosystems is advancing clinical development of its MagSense® pla orm technology to revolu onize cancer diagnosis, introducing molecular imaging to MRI. The Company’s lead program has demonstrated its innova ve technology embodied in MagSense® HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in pa ents diagnosed with HER2+ breast cancer. Imagion Biosystems’ MagSense® pipeline includes prostate cancer, ovarian cancer, pancrea c cancer, and brain cancer programs. For more informa on, visit h ps://imagionbiosystems.com/investor-hub/ Imagion Biosystems InteracƟve Investor Hub Engage with us directly by asking ques ons, watching video summaries, and seeing what other shareholders have to say about this and past announcements at our Investor Hub: h ps://investorhub.imagionbiosystems.com/ AuthorisaƟon & AddiƟonal informaƟon This announcement was authorised by the Company Secretary of Imagion Biosystems Limited. Australian Media & Investor RelaƟons: Geoff Hollis, CFO and Company Secretary geoff.hollis@imagionbio.com +61 438 168 008 U.S. Media Contact Casie Ost casie.ost@imagionbio.com +1-619-693-4428 INTERNAL USE ONLY # Imagion Biosystems Limited Extraordinary General Meeting Monday, 13 November 2023 Results of Meeting The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2. Resolution details Resolution Resolution Type Instructions given to validly appointed proxies (as at proxy close) Proxy's For Against Abstain Discretion For Against Abstain* 1. Election of Director - Dr Isaac Bright Ordinary 92,899,270 83.59% 6,256,747 5.63% 11,981,839 10.78% 4,614,914 114,096,359 94.80% 6,256,747 5.20% 4,614,914 2. Consolidation of capital of the Company Ordinary 66,690,019 57.66% 38,092,320 32.94% 10,872,931 9.40% 97,500 86,770,200 69.49% 38,100,320 30.51% 97,500 3. Approval of the future issue of Subsequent Tranche Convertible Notes and Subsequent Tranche Options to Mercer Street Global Opportunity Fund, LLC Ordinary 73,126,439 64.30% 27,911,615 24.54% 12,685,002 11.15% 2,029,714 93,471,691 76.03% 29,466,615 23.97% 2,029,714 4. Approval of issue of Options to Directors Ordinary 62,639,952 54.75% 40,261,945 35.19% 11,516,839 10.07% 770,034 74,164,791 63.95% 41,816,945 36.05% 770,034 5. Approval of issue of Options to Dr Isaac Bright Ordinary 77,743,316 67.26% 26,671,620 23.08% 11,171,334 9.66% 147,500 96,574,900 77.38% 28,226,620 22.62% 147,500 6. Amendment of Constitution - increase Employee Incentive cap Special 74,095,193 64.81% 25,687,593 22.47% 14,543,195 12.72% 1,426,789 96,298,638 77.95% 27,242,593 22.05% 1,426,789 * Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. # Number of votes cast on the poll (where applicable) INTERNAL USE ONLY Resolution Result Carried / Not Carried Carried Carried Carried Carried Carried Carried